BACKGROUND: Aspirin, a non-steroidal anti-inflammatory drug and platelet inhibitor, has been shown to reduce cancer incidence, lower metastatic rates and improve survival in certain cancer types. However, data on the effect of aspirin on prognosis in pancreatic ductal adenocarcinoma (PDAC) are limited. Therefore, we conducted a retrospective, single-center study to evaluate the impact of aspirin use on disease characteristics and survival in PDAC patients. MATERIALS AND METHODS: The study analyzed data from all consecutively treated PDAC patients over a 6-year period. Operability, Tumor-Node-Metastasis (TNM) stage, and survival endpoints were compared between patients who had used aspirin for 2 or more years prior to their diagnosis (ASA ≥ 2) and those who did not (ASA 0). RESULTS: A total of 182 patients were included. In the ASA ≥ 2 group, significantly fewer patients had metastatic disease at diagnosis, and a significantly larger proportion presented in the operable stages, compared to the ASA 0 group. No significant differences were observed between the two groups in the T or N stages, overall survival, disease-free survival, or time to progression-free survival. CONCLUSIONS: Although long-term aspirin use did not influence survival endpoints, it was associated with a significantly lower probability of demonstrable distant metastases at diagnosis and a higher rate of resectable disease. This finding warrants further research to explore new therapeutic approaches for the treatment of PDAC.

3rd Department of Internal Medicine Metabolic Care and Gerontology University Hospital in Hradec Králové Czech Republic

Department of Oncology and Radiotherapy University Hospital in Hradec Králové Czech Republic

Department of Surgery University Hospital in Hradec Králové Czech Republic

Faculty of Medicine Charles University Hradec Králové Czech Republic

See more in PubMed

Siegel RL, Miller KD, Fuchs HE, et al. Cancer Statistics, 2021. CA Cancer J Clin. 2021;71(1):7–33. doi: 10.3322/caac.21654. PubMed DOI

Ferlay J, Colombet M, Soerjomataram I, et al. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer. 2018;103:356–387. doi: 10.1016/j.ejca.2018.07.005. PubMed DOI

Rahib L, Wehner MR, Matrisian LM, et al. Estimated Projection of US Cancer Incidence and Death to 2040. JAMA Netw Open. 2021;4(4):e214708. doi: 10.1001/jamanet-workopen.2021.4708. PubMed DOI PMC

Global Cancer Observatory. [08.05.2024]. https://www-dep.iarc.fr/

Dušek L, Mužík J, Kubásek M, et al. Masaryk University; [08.05.2024]. Epidemiologie Zhoubných Nádorů v České Republice [Online] http://www.svod.cz .

Yasinzai AQ, Tareen B, Tracy K, et al. Pancreatic ductal adenocarcinoma: exploring clinicopathological trends and racial disparities in a comprehensive U.S. population-based study. Clin Transl Oncol. 2024;26(10):2618–2628. doi: 10.1007/s12094-024-03484-7. PubMed DOI

Pugliese NR, Taddei S. Low-dose aspirin therapy for primary prevention of cardiovascular disease: where are we at? Eur J Prev Cardiol. 2023;30(12):1170–1171. doi: 10.1093/eurjpc/zwad110. PubMed DOI

Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;140(11):e596–e646. doi: 10.1161/CIR.0000000000000678. PubMed DOI PMC

Bosetti C, Santucci C, Gallus S, et al. Aspirin and the risk of colorectal and other digestive tract cancers: an updated meta-analysis through 2019. Ann Oncol. 2020;31(5):558–568. doi: 10.1016/j.annonc.2020.02.012. PubMed DOI

Santucci C, Gallus S, Martinetti M, et al. Aspirin and the risk of nondigestive tract cancers: An updated meta-analysis to 2019. Int J Cancer. 2021;148(6):1372–1382. doi: 10.1002/ijc.33311. PubMed DOI

Elwood PC, Morgan G, Delon C, et al. Aspirin and cancer survival: a systematic review and meta-analyses of 118 observational studies of aspirin and 18 cancers. Ecancermedicalscience. 2021;15:1258. doi: 10.3332/ecancer.2021.1258. PubMed DOI PMC

Patel J, Khanna T, Sohal A, et al. Impact of aspirin use on rates of metastasis in patients with esophageal cancer: insights from the National Inpatient Sample. Dis Esophagus. 2024;37(7) doi: 10.1093/dote/doae022. PubMed DOI

Shiao J, Thomas KM, Rahimi AS, et al. Aspirin/antiplatelet agent use improves disease-free survival and reduces the risk of distant metastases in Stage II and III triple-negative breast cancer patients. Breast Cancer Res Treat. 2017;161(3):463–471. doi: 10.1007/s10549-016-4081-8. PubMed DOI

Rothwell PM, Wilson M, Price JF, et al. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet. 2012;379(9826):1591–1601. doi: 10.1016/S0140-6736(12)60209-8. PubMed DOI

Anderson KE, Johnson TW, Lazovich D, et al. Association between nonsteroidal anti-inflammatory drug use and the incidence of pancreatic cancer. J Natl Cancer Inst. 2002;94(15):1168–1171. doi: 10.1093/jnci/94.15.1168. PubMed DOI

Streicher SA, Yu H, Lu L, et al. Case-control study of aspirin use and risk of pancreatic cancer. Cancer Epidemiol Biomarkers Prev. 2014;23(7):1254–1263. doi: 10.1158/1055-9965.EPI-13-1284. PubMed DOI PMC

Risch HA, Lu L, Streicher SA, et al. Case-control study of aspirin use and risk of pancreatic cancer. Cancer Epidemiol Biomarkers Prev. 2014;23(7):1254–1263. doi: 10.1158/1055-9965.EPI-13-1284. PubMed DOI PMC

Menezes RJ, Huber KR, Mahoney MC, et al. Regular use of aspirin and pancreatic cancer risk. BMC Public Health. 2002;2:18. doi: 10.1186/1471-2458-2-18. PubMed DOI PMC

Bonifazi M, Gallus S, Bosetti C, et al. Aspirin use and pancreatic cancer risk. Eur J Cancer Prev. 2010;19(5):352–354. doi: 10.1097/CEJ.0b013e32833b48a4. PubMed DOI

Kho PF, Fawcett J, Fritschi L, et al. Nonsteroidal anti-inflammatory drugs, statins, and pancreatic cancer risk: a population-based case-control study. Cancer Causes Control. 2016;27(12):1457–1464. doi: 10.1007/s10552-016-0824-4. PubMed DOI

Hackner D, Hobbs M, Merkel S, et al. Impact of Aspirin Intake on Postoperative Survival after Primary Pancreatic Resection of Pancreatic Ductal Adenocarcinoma-A Single-Center Evaluation. Biomedicines. 2023;11(5) doi: 10.3390/biomedicines11051466. PubMed DOI PMC

Pretzsch E, D’Haese JG, Renz B, et al. Effect of platelet inhibition with perioperative aspirin on survival in patients undergoing curative resection for pancreatic cancer: a propensity score matched analysis. BMC Surg. 2021;21(1):98. doi: 10.1186/s12893-021-01083-9. PubMed DOI PMC

Tamburrino D, Guarneri G, Pagnanelli M, et al. Chemo-preventive Agents After Pancreatic Resection for Ductal Adenocarcinoma: Legend or Scientific Evidence? Ann Surg Oncol. 2021;28(4):2312–2322. doi: 10.1245/s10434-020-09097-y. PubMed DOI

Frouws MA, Bastiaannet E, Langley RE, et al. Effect of low-dose aspirin use on survival of patients with gastrointestinal malignancies; an observational study. Br J Cancer. 2017;116(3):405–413. doi: 10.1038/bjc.2016.425. PubMed DOI PMC

Wang L, Zhang R, Yu L, et al. Aspirin Use and Common Cancer Risk: A Meta-Analysis of Cohort Studies and Randomized Controlled Trials. Front Oncol. 2021;11:690219. doi: 10.3389/fonc.2021.690219. PubMed DOI PMC

Mezouar S, Frère C, Darbousset R, et al. Role of platelets in cancer and cancer-associated thrombosis: Experimental and clinical evidences. Thromb Res. 2016;139:65–76. doi: 10.1016/j.thromres.2016.01.006. PubMed DOI

Chen Y, Zhou J, Liu Z, et al. Tumor cell-induced platelet aggregation accelerates hematogenous metastasis of malignant melanoma by triggering macrophage recruitment. J Exp Clin Cancer Res. 2023;42(1):277. doi: 10.1186/s13046-023-02856-1. PubMed DOI PMC

Zhao J, Huang A, Zeller J, et al. Decoding the role of platelets in tumour metastasis: enigmatic accomplices and intricate targets for anticancer treatments. Front Immunol. 2023;14:1256129. doi: 10.3389/fimmu.2023.1256129. PubMed DOI PMC

Li Y, Wang H, Zhao Z, et al. Effects of the interactions between platelets with other cells in tumor growth and progression. Front Immunol. 2023;14:1165989. doi: 10.3389/fimmu.2023.1165989. PubMed DOI PMC

Wang X, Zhao S, Wang Z, et al. Platelets involved tumor cell EMT during circulation: communications and interventions. Cell Commun Signal. 2022;20(1):82. doi: 10.1186/s12964-022-00887-3. PubMed DOI PMC

Gkolfinopoulos S, Jones RL, Constantinidou A. The Emerging Role of Platelets in the Formation of the Micrometastatic Niche: Current Evidence and Future Perspectives. Front Oncol. 2020;10:374. doi: 10.3389/fonc.2020.00374. PubMed DOI PMC

Braun A, Anders HJ, Gudermann T, et al. Platelet-Cancer Interplay: Molecular Mechanisms and New Therapeutic Avenues. Front Oncol. 2021;11:665534. doi: 10.3389/fonc.2021.665534. PubMed DOI PMC

Wojtukiewicz MZ, Sierko E, Hempel D, et al. Platelets and cancer angiogenesis nexus. Cancer Metastasis Rev. 2017;36(2):249–262. doi: 10.1007/s10555-017-9673-1. PubMed DOI PMC

Chater C, Bauters A, Beugnet C, et al. Intraplatelet Vascular Endothelial Growth Factor and Platelet-Derived Growth Factor: New Biomarkers in Carcinoembryonic Antigen-Negative Colorectal Cancer? Gastrointest Tumors. 2018;5(1–2):32–37. doi: 10.1159/000486894. PubMed DOI PMC

Wood S, Hilgard P. Aspirin and tumour metastasis. Lancet. 1972;2(7792):1416–1417. doi: 10.1016/s0140-6736(72)92982-0. PubMed DOI

Henschke UK, Luande GJ, Choppala JD. Aspirin for reducing cancer metastases? J Natl Med Assoc. 1977;69(8):581–584. PubMed PMC

Sharpe CR, Collet JP, McNutt M, et al. Nested case-control study of the effects of non-steroidal anti-inflammatory drugs on breast cancer risk and stage. Br J Cancer. 2000;83(1):112–120. doi: 10.1054/bjoc.2000.1119. PubMed DOI PMC

Leitzmann MF, Stampfer MJ, Ma J, et al. Aspirin use in relation to risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2002;11(10 Pt 1):1108–1111. PubMed

Guo CG, Ma W, Drew DA, et al. Aspirin use and survival after diagnosis of colorectal cancer. JAMA. 2009;302(6):649–658. doi: 10.1001/jama.2009.1112. PubMed DOI PMC

Tomasello G, Ghidini M, Costanzo A, et al. Outcome of head compared to body and tail pancreatic cancer: a systematic review and meta-analysis of 93 studies. J Gastrointest Oncol. 2019;10(2):259–269. doi: 10.21037/jgo.2018.12.08. PubMed DOI PMC